eric topol glp-1 Straight Talk with Daniel Drucker on GLP-1: Ground Truths Podcast with The GLP-1 era in medicine

It protects nerves and works well with B12

These agents are believed to suppress presynaptic dopamine release and dampen postsynaptic reward signaling at mesolimbic synapses, thereby diminishing the reinforcing effects of alcohol consumption

[12] [13] The SELECT trial with semaglutide showed cardiovascular benefits in a population with established cardiovascular disease but did not specifically address outcomes in patients with decompensated heart failure

The drug won a priority review voucher from the agency, which could mean the agency will make a decision "within months." Novo Nordisk and Eli Lilly are also working on the next generation of these drugs, which could prove to be even more effective than the ones already on the market